Effect of sesamin in Acanthopanax senticosus Harms on behavioral dysfunction in rotenone-induced parkinsonian rats

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 1, 2005, Pages 169-172

  Fujikawa, Takahiko ^a   Kanada, Nariyasu ^a   Shimada, Akihide ^a   Ogata, Masato ^a   Suzuki, Ikukatsu ^b   Hayashi, Ikuo ^b   Nakashima, Kunio ^c  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c TOKAI GAKUEN UNIVERSITY   (Japan)

Author keywords

Acanthopanax senticosus; Bradykinesia; Catalepsy; Parkinson's disease; Rotenone; Sesamin

Indexed keywords

ACANTHOPANAX SENTICOSUS EXTRACT; NEUROTOXIN; PLANT EXTRACT; ROTENONE; SESAMIN; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; LIGNAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BRADYKINESIA; CATALEPSY; CELL PROTECTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG INDUCED DISEASE; ELEUTHEROCOCCUS SENTICOSUS; MALE; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PROPHYLAXIS; RAT; SUBSTANTIA NIGRA; ACANTHOPANAX; ANIMAL; BARK; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DEPRESSION; ISOLATION AND PURIFICATION; LEWIS RAT; PARKINSONISM; PSYCHOLOGICAL ASPECT;

ACANTHOPANAX; ANIMALS; DEPRESSIVE DISORDER; DIOXOLES; LIGNANS; MALE; PARKINSONIAN DISORDERS; PLANT BARK; PLANT EXTRACTS; RATS; RATS, INBRED LEW; ROTENONE;

EID: 18444371726     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.169     Document Type: Article

References (15)

1. Brekhman I. I., Invest. Sibir. Otdel. Acad. Nauk. U.S.S.R., 9, 113-117 (1969).
2. Fujikawa T., Yamaguchi A., Morita I., Takeda H., Nishibe S., Biol. Pharm. Bull., 19, 1227-1230 (1996).
3. Yi J.-M., Hong S.-H., Kim J.-H., Kim H.-K., Song H.-J., Kim H.-M., J. Ethnopharm., 79, 347-352 (2002).
4. Jung H. J., Park H. J., Kim R. G., Shin K. M., Ha J., Choi J. W., Kim H. J., Lee Y. S., Lee K. T., Planta Med., 69, 610-616 (2003).
5. Hibasami H., Fujikawa T., Takeda H., Nishibe S., Satoh T., Fujisawa T., Nakashima K., Oncology Report, 7, 1213-1216 (2000).
6. 2O-HCOOH (50: 50: 0.1); flow rate, 0.5 ml/min; detection, UV at 285 nm; room temperature) was carried out and the results are as follows: CHA, 1632.8 μg; SYG, 1370.8 μg; syringin, 531.3 μg; sesamin, 9.6 μg in ASH extract (100 mg).
7. Fujikawa T., Soya H., Hibasami H., Kawashima H., Takeda H., Nishibe S., Nakashima K., Phytother. Res., 16, 474-478 (2002).
8. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V., Greenamyre J. T., Nature Neurosci., 3, 1301-1306 (2000).
9. Smith A. D., Kozlowski D. A., Bohn M. C., Zigmond M. J., SFN Abstract, 198.7 (2001).
10. Choi-Lundberg D. L., Lin Q., Chang Y. N., Chiang Y. L., Ha C. M., Mohajeri H., Davidson B. L., Bohn M. C., Science, 275, 838-841 (1997).
11. Kozlowski D. A., Connor B., Tillerson J. L., Schallert T., Bohn M. C., Exp. Neurol., 166, 1-15 (2000).
12. Ogawa N., Hirose Y., Ohara S., Ono T., Watanabe Y., Pathol. Pharmacol., 50, 435-441 (1985).
13. Viyoch J., Ohdo S., Yukawa E., Higuchi S., J. Pharmacol. Exp. Ther. 298, 964-969 (2001).
14. Pochon N. A., Menoud A., Tseng J. L., Zurn A. D., Aebischer P., Eur. J. Neurosci., 9, 463-471 (1997).
15. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P. A., Collins F., Hoffer B. J., Gerhardt G. A., Nature (London), 380, 252-255 (1966).